Search results
Showing 31 to 45 of 70 results for hepatocellular carcinoma
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Irreversible electroporation for primary liver cancer (HTG532)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for HTG532Show all sections
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.
View recommendations for HTG83Show all sections
Sections for HTG83
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Discontinued Reference number: GID-TA10811
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued Reference number: GID-TA10259